Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
Mexiletine
Mexiletine · MEXILETIN · C07220 · Mexilux · Mexilitine · Mexiletene · Mexilitine R · dl-Mexiletine
식별자 및 물리적 특성
| CAS No. | 31828-71-4 |
|---|---|
| 분자식 | C11H17NO |
| 평균 분자량 | 179.26 g/mol |
| 단동위원소 질량 | 179.13101417 g/mol |
| SMILES | Cc1cccc(C)c1OCC(C)N |
| InChIKey | VLPIATFUUWWMKC-UHFFFAOYSA-N |
| PubChem CID | 4178 |
| ChEMBL | CHEMBL558 |
| ChEBI | CHEBI:6916 |
| EC No. | 250-825-7 |
| DTXSID | DTXSID8048446 |
화학 및 물리적 성질
| XLogP | 2.1 |
|---|---|
| 극성 표면적 | 35.3 |
| 수소 결합 공여자 수 | 1 |
| 수소 결합 수용자 수 | 2 |
| 회전 가능 결합 수 | 3 |
| 무거운 원자 수 | 13 |
| 형식 전하 | 0 |
| 복잡도 | 139 |
| 의약품 | Pharmaceuticals |
| LogP(분배 계수) | 2.12.15 |
| 용해도 | 5.38e-01 g/L에탄올: 50mg/mL |
| Human Drugs | Breast FeedingLactationMilk, HumanAntiarrhythmicsEMA approved medicines: Human medicine (Orphan designations) |
| 녹는점 | 203-205 °C203 - 205 °C |
| Physical Description | Solid |
| Dissociation Constants | 9.149.159.2 |
| Collision Cross Section | 145.11 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards] |
| 끓는 점 | 271.5±28.0 °C(Predicted) |
| 밀도 | 0.979±0.06 g/cm3(Predicted) |
| 저장 조건 | 2-8°C |
| pKa(산도 계수) | pKa 9.14± 0.01(H2O,t =25±0.2,I=0.01(NaCl))(Approximate) |
| 물리적 상태 | 가루 |
| 색상 | 하얀색 |
| BCS Class | 1 |
| NIST | Mexiletine(31828-71-4) |
안전 및 규제
| GHS 분류 | WarningH302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 2 reports by companies from 1 notifications to the ECHA C&L Inventory. |
|---|---|
| 규제 정보 | REACH registered substance: Mexiletine (EC: 250-825-7) |
| Hazard Classes and Categories | Acute Tox. 4 (100%) |
| Hepatotoxicity | In clinical trials, mexiletine was associated with a low rate of serum aminotransferase and alkaline phosphatase elevations (~0.5%). Despite wide scale use, mexiletine has only rarely been linked to cases of clinically apparent liver injury. Most cases are associated with a hypersensitivity reaction. Typically, patients present with fever, rash, eosinophilia and systemic systemics (DRESS syndrome) after 2 to 6 weeks of mexiletine therapy. Eosinophilia or atypical lymphocytosis usually accompany the liver test abnormalities but may arise or continue to worsen days or weeks after onset. The pattern of serum enzyme elevations ranges from cholestatic to hepatocellular, but jaundice is usually mild or absent. Autoimmune features are uncommon. Cases of Stevens Johnson and DRESS syndrome due to mexiletine have also been reported. Corticosteroids were often used, but largely for the fever and skin rash rather than the liver disease which was typically mild. Rare instances of cholestatic hepatitis with mexiletine therapy have also been reported and may represent a different form of liver injury. |
| 유해 작용 | The adverse effect profile of mexiletine is extensive and limits its use. It affects nearly every organ systemmost notably, it has significant cardiovascular and central nervous system (CNS) side effects and affecting the gastrointestinal (GI), musculoskeletal, dermatologic systems. |
| 독성 요약 | Toxicity is common with mexiletine and can manifest in several organ systems. Cardiovascular, CNS, and GI-related symptoms most commonly occur. Cardiovascular toxicity can present as varying degrees of heart block, heart failure, exacerbation of cardiac arrhythmias, and cardiac arrest. Central nervous system-related symptoms include lightheadedness, fatigue, confusion, the presence of tremors, and seizures. Gastrointestinal symptoms are highly variable but can include xerostomia, nausea/vomiting, and diarrhea. Mexiletine has a half-life of 10 to 12 hours and is metabolized by the liver with small amounts, about 10% of the administered dose, of excretion in the urine. Thus, toxicity is much more prevalent in the setting of liver failure as metabolism is largely impaired. |
용도
용도
Cardiac depressant (anti-arrhythmic).